Daily oxymetazoline cream demonstrates high and sustained efficacy in patients with persistent erythema of rosacea through 52 weeks of treatment - 16/08/18
Doi : 10.1016/j.jaad.2018.05.037
Michael H. Gold, MD a, ⁎ 
, Mark Lebwohl, MD b, Brian S. Biesman, MD c, Deanne Mraz Robinson, MD d, Lei Luo, MPH e, David R. Berk, MD e, Gurpreet Ahluwalia, PhD e, Nancy Alvandi, PhD e
, Mark Lebwohl, MD b, Brian S. Biesman, MD c, Deanne Mraz Robinson, MD d, Lei Luo, MPH e, David R. Berk, MD e, Gurpreet Ahluwalia, PhD e, Nancy Alvandi, PhD e a Tennessee Clinical Research Center, Nashville, Tennessee
b Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York
c Private practice, Nashville, Tennessee
d Connecticut Dermatology Group, Norwalk, Connecticut
e Allergan plc, Irvine, California
∗Correspondence to: Michael H. Gold, MD, Tennessee Clinical Research Center, 2000 Richard Jones Rd, Ste 220, Nashville, TN 37215Tennessee Clinical Research Center2000 Richard Jones RdSte 220NashvilleTN37215
Le texte complet de cet article est disponible en PDF.
| Funding sources: Supported by Allergan plc, Dublin, Ireland. Writing and editorial assistance was also funded by Allergan plc. Neither honoraria nor other form of payments were made for authorship. |
|
| Conflicts of interest: Drs Gold, Biesman, and Robinson are investigators for Allergan plc. Dr Lebwohl is an employee of Icahn School of Medicine at Mount Sinai, which receives research funds from Abbvie, Amgen, Boehringer Ingelheim, Celgene, Eli Lilly, Janssen/Johnson & Johnson, Kadmon, Medimmune/AstraZeneca, Novartis, Pfizer, Valeant, and Vidac. Dr Lebwohl is a consultant for Allergan plc, Aqua, Leo Pharma, and Promius. Mr Luo, Dr Berk, and Dr Alvandi are employees of Allergan plc, and Dr Ahluwalia was an employee of Allergan plc at the time the analysis was conducted; all might own stock or stock options in that company. |
© 2018
American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 79 - N° 3
P. e57-e59 - septembre 2018 Retour au numéro
Article précédent
- Reply to: “Comment on ‘Prognostic value of sentinel lymph node biopsy according to Breslow thickness for cutaneous melanoma’”
- Evan Stiegel, Alok Vij
- September iotaderma (#295)
- Robert I. Rudolph
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?